Shire PLC (NASDAQ:SHPG) – Analysts at Leerink Swann dropped their Q3 2016 earnings per share estimates for Shire PLC in a research note issued to investors on Monday. Leerink Swann analyst J. Gerberry now anticipates that the brokerage will post earnings of $3.40 per share for the quarter, down from their previous estimate of $3.43. Leerink Swann has a “Outperform” rating and a $231.00 price objective on the stock.
A number of other research firms also recently weighed in on SHPG. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a report on Tuesday. Jefferies Group reissued a “buy” rating and set a $262.00 price target on shares of Shire PLC in a report on Wednesday, September 7th. BTIG Research reissued a “buy” rating and set a $230.00 price target on shares of Shire PLC in a report on Tuesday, July 12th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Shire PLC in a report on Friday, June 3rd. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $230.67.
Shares of Shire PLC (NASDAQ:SHPG) opened at 199.57 on Wednesday. The stock has a market capitalization of $59.44 billion, a PE ratio of 41.47 and a beta of 1.11. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The company’s 50-day moving average is $196.34 and its 200-day moving average is $185.44.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. During the same period in the prior year, the company earned $2.63 EPS. The firm’s revenue was up 55.9% on a year-over-year basis.
The firm also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be given a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.
Several hedge funds have recently made changes to their positions in SHPG. Quadrant Capital Group LLC raised its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the period. Canal Insurance CO purchased a new stake in Shire PLC during the second quarter valued at about $102,000. FTB Advisors Inc. raised its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. purchased a new stake in Shire PLC during the second quarter valued at about $111,000. Finally, Ropes Wealth Advisors LLC purchased a new stake in Shire PLC during the second quarter valued at about $114,000. 24.26% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.